After a dismal 2024, CVS Health (NYSE:CVS) could be starting to turn itself around. Some investors seem convinced, especially after the retail drugstore chain on Wednesday posted a big beat on ...

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Encompass Health (EHC – Research Report), with a ...

A Leerink analyst says CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits ...

Truist Financial analyst David S Macdonald reiterated a Buy rating on CVS Health (CVS – Research Report) today and set a price target of ...

CVS appears uniquely positioned to improve health outcomes, and we appreciate management's focus on better leveraging its assets through digital and other means to bring a more consumer-centric ...

CVS Health steered through rising costs in its insurance division to handily beat profit expectations on Wall Street.

CVS Health posted Q4 sales of $97.71B, with a 23.3% rise in Health Care Benefits revenue. Fiscal 2025 adjusted EPS guidance ...

Pharmacy retailer CVS Health Inc. (NYSE:CVS) is scheduled to report its fourth quarter 2024 earnings on Wednesday,2. Wall ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Humana’s outlook isn’t great, but performance in the fourth quarter was a bit better than expected. Despite the beat, however ...

Healthcare startup Capital Rx seeing revenue surge as Congress seeks to regulate the PBM giants that profit from high drug ...